Wahl Bryan 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Dec 1, 2023
Insider Transaction Report
Form 4
Wahl Bryan
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2023-11-29+23,920→ 40,322 total - Sale
Common Stock
2023-11-30$16.31/sh−8,356$136,286→ 31,966 total - Exercise/Conversion
Restricted Stock Units
2023-11-29−23,920→ 0 total→ Common Stock (23,920 underlying)
Footnotes (3)
- [F1]The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2023.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]RSUs granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 30% of the RSUs vested on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service.